从绿色链霉菌中生产阿霉素的局限性。
Limitations in doxorubicin production from Streptomyces peucetius.
机构信息
Institute of Biomolecule Reconstruction (iBR), Department of Pharmaceutical Engineering, Sun Moon University, #100, Kalsan-ri, Tangjeong-myeon, Asansi, Chungnam 336-708, Korea (ROK).
出版信息
Microbiol Res. 2010 Jul 20;165(5):427-35. doi: 10.1016/j.micres.2009.11.006. Epub 2010 Jan 29.
Doxorubicin (DXR), produced by Streptomyces peucetius ATCC 27952, exhibits potent antitumor activity against various cancer cell lines. Considerable time has lapsed since the biosynthesis of DXR and its overproduction was first summarized. Based on biosynthetic studies and product analysis, various factors affecting its production by the parental strain, S. peucetius ATCC 27952, are reviewed to better circumvent any bottlenecks in DXR production, thereby providing ideas to genetically engineered industrial strains of S. peucetius.
多柔比星（DXR）由吸水链霉菌（Streptomyces peucetius）ATCC 27952 产生，对各种癌细胞系具有很强的抗肿瘤活性。自从首次总结多柔比星的生物合成及其过量生产以来，已经过去了相当长的时间。基于生物合成研究和产物分析，本文综述了影响原始菌株吸水链霉菌（Streptomyces peucetius）ATCC 27952 生产多柔比星的各种因素，以更好地克服多柔比星生产中的任何瓶颈，从而为吸水链霉菌的基因工程工业菌株提供思路。
Zotero 插件